Completed A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors NCT03546894 Conditions Anaplastic Lymphoma Kinase-positive, Bronchial Neoplasms, Carcinoma Non-small-cell Lung, +9 more Locations EmpiraMed, Inc. — Maynard, Massachusetts, United States View Trial Details
